Haw. Code R. §§ 11-266.509 - Shipping potentially creditable hazardous waste pharmaceuticals from a healthcare facility or a reverse distributor to a reverse distributor
(a) Shipping potentially creditable hazardous
waste pharmaceuticals. A healthcare facility or a reverse distributor who
transports or offers for transport potentially creditable hazardous waste
pharmaceuticals offsite to a reverse distributor must comply with all
applicable U.S. Department of Transportation regulations in 49 CFR part 171
through 180 for any potentially creditable hazardous waste pharmaceutical that
meets the definition of hazardous material in
49 CFR
171.8. For purposes of the Department of
Transportation regulations, a material is considered a hazardous waste if it is
subject to the Hazardous Waste Manifest Requirements of the U.S. Environmental
Protection Agency specified in 40 CFR part 262 [federal]. Because a potentially
creditable hazardous waste pharmaceutical does not require a manifest, it is
not considered hazardous waste under the Department of Transportation
regulations.
(b) Delivery
confirmation. Upon receipt of each shipment of potentially creditable hazardous
waste pharmaceuticals, the receiving reverse distributor must provide
confirmation (paper or electronic) to the healthcare facility or reverse
distributor that initiated the shipment that the shipment of potentially
creditable hazardous waste pharmaceuticals has arrived at its destination and
is under the custody and control of the reverse distributor.
(c) Procedures for when delivery confirmation
is not received within 35 calendar days. If a healthcare facility or reverse
distributor initiates a shipment of potentially creditable hazardous waste
pharmaceuticals to a reverse distributor and does not receive delivery
confirmation within 35 calendar days from the date that the shipment of
potentially creditable hazardous waste pharmaceuticals was sent, the healthcare
facility or reverse distributor that initiated the shipment must contact the
carrier and the intended recipient (i.e., the reverse distributor) promptly to
report that the delivery confirmation was not received and to determine the
status of the potentially creditable hazardous waste pharmaceuticals.
(d) Exporting potentially creditable
hazardous waste pharmaceuticals. A healthcare facility or reverse distributor
that sends potentially creditable hazardous waste pharmaceuticals to a foreign
destination must comply with the applicable sections of 40 CFR part 262 subpart
H, except the manifesting requirement of § 262.83(c), in addition to
paragraphs (a) through (c) of this section.
(e) Importing potentially creditable
hazardous waste pharmaceuticals. Any person that imports potentially creditable
hazardous waste pharmaceuticals into the United States is subject to paragraphs
(a) through (c) of this section in lieu of 40 CFR part 262 subpart H.
Immediately after the potentially creditable hazardous waste pharmaceuticals
enter the United States, they are subject to all applicable requirements of
this subpart.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.